System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Michael Gnant is an expert in Oncology at Comprehensive Cancer Center Vienna (Austria). As of October 2026, ScienceLeadR ranks Michael Gnant in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Michael Gnant has authored 811 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 2 of them ongoing. SLR score: 2,835 (community average: 125). How the SLR is computed.

LeadR Profile

Michael Gnant Comprehensive Cancer Center Vienna Austria
2 835 ScienceLeadR Reputation 2835

Unlock

Register Login
Network Map

Oncology

Subspecialties: Surgery - Dermatology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1989 - 2026
Source: PubMed

Medical University of Vienna

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 811

Citations

Citations: 72 016 1st author: 91 Last author: 139 Unique author: 43

Main journals

J Clin Oncol 98
Cancer Res 83
Ann Oncol 64
Eur J Cancer 38
Breast Care (Basel) 37

Best Journals

Lancet Oncol 22
J Clin Oncol 21
Ann Oncol 17

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Omitting axillary dissection in breast cancer patients with one to two positive sentinel nodes undergoing mastectomy: a retrospective and prospective cohort study with a target trial emulation.
PMID 42682276 — mastectomy, lymph nodes, breast neoplasms, neoplasms, cohort studies, sentinel lymph node, neoplasm metastasis, lymph, breast, sentinel lymph node biopsy, dissection		Int J Surg20260
The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer.
PMID 42497534 — genes, lymph nodes, breast neoplasms, neoplasms, lymph, breast		Clin Breast Cancer20260
Common analysis pitfalls in longitudinal ctDNA studies: lead time, sensitivity and immortal time bias.
PMID 42508231 — bias, biomedical research		EBioMedicine20261
Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial.
PMID 42308863 — estrogens, body mass index, breast neoplasms, receptors, estrogen, neoplasms, letrozole, breast, obesity, breast density, overweight		Eur J Cancer20260
Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancer.
PMID 42266036 — poly(adp-ribose) polymerases, breast neoplasms, pharmaceutical preparations, neoplasms, poly adenosine diphosphate ribose, breast, therapeutics		Oncologist20260

Clinical Studies 25

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2 Study Chair: 2 Study Director: 1

By phase:

Phase 3 15
N/A 5
Phase 2 5

By status:

Completed 19
Active not recruiting 4
Recruiting 1
Terminated 1

By type:

Interventional 24
Observational 1

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 2
multicentricup10 19

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Independent External Blinded Retrospective Validation of an AI based Prognostic Assay in ER Positive HER2 Negative Early Breast Cancer
NCT07541703 — telepathology, intelligence, breast neoplasms, neoplasms, pathology, breast, therapeutics, artificial intelligence, landslides		N/AActive not recruiting2026
ABCSG 61 TEODOR Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness
NCT07084558 — quality of life, aromatase, blood, circulating tumor dna, aromatase inhibitors, breast neoplasms, blood specimen collection, neoplasms, biopsy, drug therapy, chemotherapy, adjuvant, breast, neoadjuvant therapy, therapeutics, artificial intelligence, dna, tamoxifen, chemotherapy		N/ARecruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS